Outcomes 2016 - Baylor Hamilton Heart and Vascular Hospital FY 2016 | Page 55
Complex Dialysis Access: Experience with Complex Bypasses
and Fistulas for Complex Hemodialysis Access
Clinical studies and continued research in the area of complex
dialysis access is a mainstay for the vascular surgery division.
In fiscal year 2016, vascular surgeons on the medical staff
realized increasing volumes in referrals from throughout Texas
for complex dialysis access procedures. The ability to handle
the complexity of the patients needing these procedures and
the experience of the vascular surgeons on the medical staff
are known nationwide to training surgeons interested in
completing a vascular surgery fellowship at Baylor University
Medical Center at Dallas and Baylor Hamilton Heart and
Vascular Hospital. With the support of an experienced and
certified ultrasonography team for diagnostic support, vascular
surgeons provide a wide array of surgical interventions.
In fiscal year 2016, the team worked with the National Kidney
Foundation for the “Fistula First” initiative. The vascular
surgeons are proud to be a part of the national goal of providing
fistulas for our End-Stage Renal Disease population and in
line with the goals of the National Kidney Foundation Kidney
Disease Outcomes Quality Initiative (NKF NDOQI)™.
HUMAN ACELLULAR VESSEL PHASE III
CLINICAL STUDY
Working closely with Humacyte, a biotechnology and
regenerative medicine company, vascular surgeons on the
medical staff at Baylor Hamilton Heart and Vascular Hospital
are involved in an investigational human acellular vessel (HAV)
Phase III clinical study as a conduit for hemodialysis in patients
with End-Stage Renal Disease and not candidates for a fistula.
Baylor Dallas is part of the largest studies of any bioengineered
vascular tissues to date. According to study information,
HUMACYL may offer a potential safe and effective alternative
for vascular access in hemodialysis treatment. The Baylor Dallas
site Primary Investigator is Stephen Hohmann, MD, FACS.
ENDOVASCULAR TREATMENT: MINIMALLY
INVASIVE SURGERY
Also, during the past year, vascular surgeons remained on
the forefront of the Super HeRO and HeRO related dialysis
access devices via Merit Medical Systems. Super HeRO was
scheduled for late 2016 release in the United States. Research
associated with the devices occurred within Baylor Hamilton
Heart and Vascular Hospital operating suites.
The importance of this for the future of vascular surgery is
evident to Stephen Hohmann, MD, director of the Vascular
Surgery Fellowship program. “It provides an option for
patients who have been told that there is no other option,” says
Dr. Hohmann. “Our involvement in leading edge techniques
and devices propels our program into nation-wide exposure
especially for our vascular surgery fellowship program.”
Hung Chu, MD, a vascular surgeon on the medical staff
and study investigator involved in HeRO, says, “HeRO is
indicating that there is a decreased risk as it avoids high-risk
dialysis access catheters. HeRO offers an option for continued
dialysis access for end-stage renal disease.” Throughout fiscal
year 2016, vascular surgeons on the medical staff at Baylor
Dallas worked closely with a multidisciplinary team on this
evolving procedure. Patient outcomes are monitored closely
and the study oversight continues.
We are a part of an exciting new technology in the way
vascular procedures may be performed in the future.
Once again, the vascular surgeons on the medical staff
at Baylor University Medical Center are on the leading
edge of vascular surgery, and we look forward to
bringing this to our vascular surgery fellows.
Stephen Hohmann, MD, FACS
Program Director, Vascular Surgery Fellowship program
*Image courtesy of Merit Medical
OUTCOMES 2016
53